Related Experiment Video
Updated: Jul 8, 2026
09:29
Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
Published on: August 21, 2017
[Neuromyelitis optica: the disease entity, pathogenesis and therapy]
1Department of Multiple Sclerosis Therapeutics, Tohoku University Graduate School of Medicine.
Rinsho Shinkeigaku = Clinical Neurology
|January 24, 2008
Summary
Neuromyelitis optica (NMO) is distinct from multiple sclerosis (MS), with specific biomarkers like anti-aquaporin-4 antibodies. Differentiating NMO from optic-spinal MS is crucial for effective treatment strategies.
Area of Science:
- Neuroimmunology
- Neurology
- Autoimmune Diseases
Context:
- Neuromyelitis optica (NMO) presents with severe optic neuritis and transverse myelitis.
- NMO shares some clinical features with multiple sclerosis (MS) but has distinct characteristics.
- Historically, recurrent NMO was termed optic-spinal MS (OSMS) in Japan.
Purpose:
- To highlight the distinct clinical and laboratory findings differentiating NMO from MS.
- To emphasize the significance of anti-aquaporin-4 (AQP4) antibodies in NMO diagnosis.
- To underscore the importance of distinguishing NMO from "genuine OSMS" for appropriate therapeutic selection.
Summary:
- NMO exhibits unique features such as female preponderance, severe disability, longitudinally extensive myelitis, CSF-pleocytosis, and negative oligoclonal IgG bands, distinguishing it from typical MS.
- The discovery of anti-AQP4 antibodies and their localization in NMO lesions strongly supports NMO as a separate entity from MS.
- Therapeutic responses differ significantly, with interferon-beta being less effective for NMO, while corticosteroids and immunosuppressants are beneficial. Plasma exchange is effective for acute exacerbations, indicating humoral immunity's role.
Impact:
- Accurate differentiation of NMO from MS and "genuine OSMS" is critical for guiding treatment decisions.
- Understanding NMO's unique pathophysiology, particularly the role of AQP4 antibodies, informs targeted therapeutic strategies.
- This distinction ensures patients receive the most effective treatments, improving outcomes for NMO and related disorders.
Related Concept Videos
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:26Encephalitis ll: Pathophysiology
Encephalitis is inflammation of the brain parenchyma caused by direct viral invasion or immune-mediated mechanisms triggered by infections or tumors. Both processes lead to neuronal injury, disrupted neurotransmission, and diverse neurological symptoms, often with overlapping clinical and pathological features.Autoimmune EncephalitisIn autoimmune encephalitis, antibodies target neuronal antigens on cell surfaces, synapses, or within neurons. A key example is anti-NMDAR encephalitis, which can...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...